Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity.
IL-5 expresses various biologic effects on several types of lymphocytes, including B cells, eosinophils, and T cells. We demonstrated that the incubation of resting splenocytes from C57BL/6 mice in murine rIL-5 enhances IL-2-mediated lymphokine-activated killer (LAK) activity against various tumor cells. IL-5 alone, however, does not induce killer activity. IL-2-mediated LAK activity increases in proportion to the dose of IL-5. During the late phase of the culture period, IL-5 seems to have some effect on the induction of IL-2-mediated LAK activity. We expect that IL-5 will prove useful for adoptive immunotherapy.
Aoki
T
T
Department of Neurosurgery, Faculty of Medicine, Kyoto University, Japan.
Kikuchi
H
H
Miyatake
S
S
Oda
Y
Y
Iwasaki
K
K
Yamasaki
T
T
Kinashi
T
T
Honjo
T
T
D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology*; D015848:Interleukin-5; D007378:Interleukins / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D008810:Mice, Inbred C57BL
D007376:Interleukin-2; D015848:Interleukin-5; D007378:Interleukins